Clinical Trial Update: Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Naxitamab + GM-CSF with isotretinoin as maintenance therapy for high-risk neuroblastoma in first complete response.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• GM-CSF (Granulocyte-macrophage colony-stimulating factor) (granulocyte-macrophage colony-stimulating factor)
• ISOTRETINOIN (Isotretinoin)
• Naxitamab (naxitamab)

Snippet

Sponsor: SciClone Pharmaceuticals | Conditions: Neuroblastoma | Phase 4 | Status: NOT_YET_RECRUITING